Genocea Biosciences Inc. (NASDAQ:GNCA) rose 3.6% during trading on Wednesday . The stock traded as high as $5.59 and last traded at $5.52, with a volume of 129,303 shares traded. The stock had previously closed at $5.33.

GNCA has been the topic of several recent research reports. FBR & Co reiterated a “buy” rating on shares of Genocea Biosciences in a research report on Friday, June 10th. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.95.

The firm’s 50-day moving average is $4.54 and its 200 day moving average is $4.45. The stock’s market capitalization is $153.57 million.

Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.05. On average, analysts expect that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.